News and Trends 11 Jun 2015
Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III
Cassiopea, Cosmo Pharmaceutical’s spin-out, will be listed on the Swiss Stock Exchange. Cosmo Pharmaceutical plans to reduce its current 97% shareholding to below the 50% bar. The majority shareholder will give away the control of its subsidiary in order to have enough cash after the end of its Phase III ACNE-treatment, currently running in the US and […]